NCT06655207View on ClinicalTrials.gov

Pivotal, Prospective, Multi-centre, Single-arm Study to Evaluate the Safety and Effectiveness of Oli for Identification of Patients, During the Intrapartum Period, Who Are at Higher Risk of Developing Abnormal Postpartum Uterine Bleeding, Including Postpartum Haemorrhage

NARecruitingINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

August 6, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

July 30, 2026

Conditions
Post Partum HaemorrhageMaternal Care PatternsHigh Risk Pregnancy
Interventions
DEVICE

Oli is a non-invasive, wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding

Oli is a non-invasive wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding, including postpartum haemorrhage.

Trial Locations (7)

2031

NOT_YET_RECRUITING

Royal Hospital for Women, Randwick

2065

RECRUITING

Royal North Shore Hospital, St Leonards

10032

NOT_YET_RECRUITING

Columbia University Irving Medical Center, New York

15213

NOT_YET_RECRUITING

UPMC Magee Womens Hospital, Pittsburgh

43210

NOT_YET_RECRUITING

The Ohio State University, Columbus

70817

NOT_YET_RECRUITING

Woman's Hospital, Baton Rouge

80045

NOT_YET_RECRUITING

UC Health University of Colorado Hospital, Denver

Sponsors
All Listed Sponsors
collaborator

Royal North Shore Hospital

OTHER

collaborator

Royal Hospital For Women

OTHER

lead

Baymatob Operations Pty Ltd

INDUSTRY

NCT06655207 - Pivotal, Prospective, Multi-centre, Single-arm Study to Evaluate the Safety and Effectiveness of Oli for Identification of Patients, During the Intrapartum Period, Who Are at Higher Risk of Developing Abnormal Postpartum Uterine Bleeding, Including Postpartum Haemorrhage | Biotech Hunter | Biotech Hunter